Abstract

BackgroundPediatric embryonal brain tumors (PEBTs), which encompass medulloblastoma (MB), primitive neuroectodermal tumor (PNET) and atypical teratoid/rhabdoid tumor (AT/RT), are the second most prevalent pediatric brain tumor type. AT/RT is highly malignant and is often misdiagnosed as MB or PNET. The distinction of AT/RT from PNET/MB is of clinical significance because the survival rate of patients with AT/RT is substantially lower. The diagnosis of AT/RT relies primarily on morphologic assessment and immunohistochemical (IHC) staining for a few known markers such as the lack of INI1 protein expression. However, in our clinical practice we have observed several AT/RT-like tumors, that fulfilled histopathological and all other biomarker criteria for a diagnosis of AT/RT, yet retained INI1 immunoreactivity. Recent studies have also reported preserved INI1 immunoreactivity among certain diagnosed AT/RTs. It is therefore necessary to re-evaluate INI1(+), AT/RT-like cases.MethodSanger sequencing, array CGH and mRNA microarray analyses were performed on PEBT samples to investigate their genomic landscapes.ResultsPatients with AT/RT and those with INI(+) AT/RT-like tumors showed a similar survival rate, and global array CGH analysis and INI1 gene sequencing showed no differential chromosomal aberration markers between INI1(−) AT/RT and INI(+) AT/RT-like cases. We did not misdiagnose MBs or PNETs as AT/RT-like tumors because transcriptome profiling revealed that not only did AT/RT and INI(+) AT/RT-like cases express distinct mRNA and microRNA profiles, their gene expression patterns were different from those of MBs and PNETs. The most similar transcriptome profile to that of AT/RTs was the profile of embryonic stem cells. However; the transcriptome profile of INI1(+) AT/RT-like tumors was more similar to that of somatic neural stem cells, while the profile of MBs was closer to that of fetal brain tissue. Novel biomarkers were identified that can be used to distinguish INI1(−) AT/RTs, INI1(+) AT/RT-like cases and MBs.ConclusionOur studies revealed a novel INI1(+) ATRT-like subtype among Taiwanese pediatric patients. New diagnostic biomarkers, as well as new therapeutic tactics, can be developed according to the transcriptome data that were unveiled in this work.Electronic supplementary materialThe online version of this article (doi:10.1186/s12920-015-0103-3) contains supplementary material, which is available to authorized users.

Highlights

  • Pediatric embryonal brain tumors (PEBTs), which encompass medulloblastoma (MB), primitive neuroectodermal tumor (PNET) and atypical teratoid/rhabdoid tumor (AT/reverse transcription (RT)), are the second most prevalent pediatric brain tumor type

  • The most similar transcriptome profile to that of atypical teratoid/rhabdoid tumor (AT/RT) was the profile of embryonic stem cells

  • Clinical features of the included primary pediatric embryonal brain tumors The diagnosis of AT/RTs and other PEBTs, especially MBs, was based on the morphologic and IHC features described in our previous reports (Additional file 1-A) [7, 14]

Read more

Summary

Introduction

Pediatric embryonal brain tumors (PEBTs), which encompass medulloblastoma (MB), primitive neuroectodermal tumor (PNET) and atypical teratoid/rhabdoid tumor (AT/RT), are the second most prevalent pediatric brain tumor type. Pediatric embryonal brain tumors (PEBTs) are the second most prevalent type of pediatric brain tumors and include medulloblastoma (MB), CNS primitive neuroectodermal tumor (CNS-PNET) and atypical teratoid/rhabdoid tumor (AT/RT). Genetic studies have shown that deletion or mutation of the INI1 gene, which is located on 22q11.2, occurs in approximately 75 % [3, 9] to 98 % [10] of AT/RTs. Immunohistochemical (IHC) staining for INI1 is considered a sensitive and highly specific approach for the diagnosis of AT/RT and in the differentiation of this tumor type from PNET and MB [11]. Retained INI1 expression (INI1 positive) was noted in all cases of PNETs/MBs [4, 9, 11,12,13]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call